Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B
| Autor: | Jordan J. Feld, Janett Fischer, Anneke J van Vuuren, Mina S Farag, Bettina E. Hansen, Florian van Bömmel, D Deichsel, Peter Ferenci, Maria Pfefferkorn, Andre Boonstra, Harry L.A. Janssen, Thomas Berg, Margo J. H. van Campenhout |
|---|---|
| Přispěvatelé: | Gastroenterology & Hepatology |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Hepatitis B virus medicine.medical_specialty Treatment response HBsAg medicine.disease_cause Antiviral Agents Gastroenterology Polyethylene Glycols law.invention 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine SDG 3 - Good Health and Well-being Randomized controlled trial Chronic hepatitis law Pegylated interferon Internal medicine Humans Medicine Hepatitis B e Antigens Hepatitis B Surface Antigens business.industry Interferon-alpha virus diseases RNA cccDNA Recombinant Proteins digestive system diseases 030104 developmental biology Infectious Diseases RNA Viral 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Clinical Infectious Diseases, 72(2), 202-211. Oxford University Press |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciaa013 |
| Popis: | Background Hepatitis B virus RNA (HBV-RNA) is a novel serum biomarker that correlates with transcription of intrahepatic covalently closed circular (cccDNA), which is an important target for pegylated interferon (PEG-IFN) and novel therapies for functional cure. We studied HBV-RNA kinetics following PEG-IFN treatment and its potential role as a predictor to response in HBeAg-negative chronic hepatitis B (CHB) patients. Methods HBV-RNA levels were measured in 133 HBeAg-negative CHB patients treated in an international randomized controlled trial (PARC study). Patients received PEG-IFN α-2a for 48 weeks. HBV-RNA was measured from baseline through week 144. Response was defined as HBV-DNA Results Mean HBV-RNA at baseline was 4.4 (standard deviation [SD] 1.2) log10 c/mL. At week 12, HBV-RNA declined by −1.6 (1.1) log10 c/mL. HBV-RNA showed a greater decline in responders compared to nonresponders early at week 12 (−2.0 [1.2] vs −1.5 [1.1] log10 c/mL, P = .04). HBV-RNA level above 1700 c/mL (3.2 log10 c/mL) had a negative predictive value of 91% at week 12 and 93% at week 24 (P = .01) for response. Overall, HBV-RNA showed a stronger correlation with HBV-DNA and HBcrAg (.82 and .80, P Conclusions During PEG-IFN treatment for HBeAg-negative CHB, HBV-RNA showed a fast and significant decline that correlates with treatment response and HBsAg loss at long-term follow-up. Clinical Trials Registration NCT00114361 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|